Similar content being viewed by others
References
Moertel CG et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321–326
O'Connell MJ et al. (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300
Haller DG et al. (1998) Fluorouracil (5FU), leucovorin and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089 [abstract]. Proc Am Soc Clin Oncol 17: a256
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944
Di Costanzo F et al. (2003) Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol 14: 1365–1372
Andre T et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903
McDermott U et al. (2003) A phase III trial of short duration adjuvant chemotherapy with bolus/infusional 5-fluorouracil (FU) and folinic acid (FA) versus surgery alone in Dukes' B and C colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 22: a1363
Chau I et al. (2005) A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: 549–557
Andre T et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351
Fisher B et al. (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483–1496
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- NCCTG
-
North Central Cancer Treatment Group
- NCIC-CTG
-
National Cancer Institute of Canada Clinical Trials Group
- IMPACT
-
International Multicentre Pooled Analysis of Adjuvant Colon Cancer Trials
- INTACC
-
Italian National Intergroup of Adjuvant Therapy Chemotherapy in Colon Cancer
- MOSAIC
-
Multicentre International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
- ESMO
-
European Society for Medical Oncology
Rights and permissions
About this article
Cite this article
Gill, S., Goldberg, R. Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. Nat Rev Clin Oncol 2, 276–277 (2005). https://doi.org/10.1038/ncponc0192
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0192
- Springer Nature Limited